ArisGen SA
This article was originally published in Start Up
Executive Summary
ArisGen SA is tackling the two most persistent issues stymieing peptide drug development: overcoming the need for injection through an oral-delivery formulation and penetrating cell membranes to reach presently undruggable targets. The company has developed two unique platform technologies: a formulation series of precision polymers, which with appropriate excipients mask the active molecule’s functional groups allowing noninvasive drug absorption, and a reversible functionalization system enabling therapeutics to selectively penetrate across membrane barriers to reach the drug’s target inside the cell.